Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Quality and safety in European Union hospitals: A research-based guide for implmeenting best practice and a framework for assessing performance (QUASER)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: United Kingdom,Sweden,Portugal,Norway,Netherlands
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-04-01
End date: 2013-06-30
Duration (months): 39.0
Total project cost (EUR): 3927104.94
EU funding (EUR): 2999842.0
Participants: 7
Project status: CLOSED

This translational study aims to design and disseminate an evidence based guide for hospitals to implement quality and safety improvement programmes, and an evidence based framework for payers to assess and monitor the quality and safety of hospitals across the EU. These outputs will be based on empirical findings from research in five partner countries. However, in addition, the development of these outputs will be with a wider stakeholder group of other countries, through a parallel process of translational workshops involving both hospitals and payers from these countries. The proposed study will take place in five European countries: Netherlands, Sweden, UK, Portugal and Norway. These countries were chosen as they represent variation in the important aspects of healthcare that we want to capture e.g. differences in the way that healthcare services are funded, and in the way that progress had been made in each country on the ‘quality journey’. By means of scoping reviews of published and grey literature, we will identify organisational and cultural characteristics which previous studies have linked to the effectiveness, safety and patient experience of hospital care and quantitative and qualitative indicators of the effectiveness, safety and patient experience of hospital care. Using results of this work, we will develop analytical tools and protocols to conduct in-depth, longitudinal case studies in a selected sample of 10 hospitals, two in each of the five partner countries. This will include building on previously published research to compare the macro-level (national) health care contexts of the five partner countries. We will then conduct a meso-level study of organisational characteristics and cultures and their relationship with available measures of the effectiveness, safety and patient experience of hospital care; and a micro-level longitudinal study of two clinical micro-systems in five of the 10 hospitals (one in each of the five partner countries). T

Keywords: patient safety,quality improvement,organisational factors,healthcare management,implementation
Discovery and preclinical development of new generation tuberculosis vaccines (NEWTBVAC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Denmark,Germany,Germany,Netherlands,Belgium,Belgium,France,Switzerland,Italy,United Kingdom,Germany,United Kingdom,France,Korea, Republic of,Spain,Germany,Netherlands,Korea, Republic of,Netherlands,Spain,United Kingdom,Italy,France,United Kingdom,Germany
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2014-02-28
Duration (months): 50.0
Total project cost (EUR): 18995943.6
EU funding (EUR): 11996730.0
Participants: 35
Project status: CLOSED

With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current control measures the Millennium Development Goals (MDGs) set for 2015 may be achieved, reaching these would still leave a million people per year dying from TB. Much more effective measures, particularly more effective vaccines will be essential to reach the target of eliminating TB in 2050. Two successive FP5 and FP6 funded projects, Tuberculosis (TB) Vaccine Cluster (2000-2003) and TBVAC (2004-2008), have in the recent decade made significant contributions to the global TB vaccine pipeline, with four vaccines (out of nine globally) being advanced to clinical stages. Both projects strongly contributed to the strengthening and integration of expertise and led to a European focus of excellence that is unique in the area of TB vaccine development. In order to sustain and accelerate the TB vaccine developments and unique integrated excellence of TBVAC, a specific legal entity was created named TuBerculosis Vaccine Initiative (TBVI). The NEWTBVAC proposal is the FP7 successor of TBVAC, and will be coordinated by TBVI. The proposal has the following objectives : 1) To sustain and innovate the current European pipeline with new vaccine discoveries and advance promising candidates to clinical stages; 2) To design new, second generation vaccines based new prime-boost strategies and/or new (combinations of) promising subunit vaccines, that will impact on reduction of disease in exposed individuals; 3) To sustain and innovate discovery, evaluation and testing of new biomarkers, that will be critically important for future monitoring of clinical trials.

Keywords: vaccine r&d tuberculosis biomarkers live vaccines sub-unit vaccines
Development of sensitive methodologies for exploitation of early epigenetic marker diagnosis in major types of cancer (EPIDIACAN)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Greece,United Kingdom,Portugal,France,Germany,Germany
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2012-12-31
Duration (months): 36.0
Total project cost (EUR): 3959200.2
EU funding (EUR): 2843859.0
Participants: 7
Project status: CLOSED

Cancer is one of the major causes of mortality. Epithelial cells become malignant after accumulating genetic mutations followed by morphological changes in the epithelium. DNA Alterations include stable genetic changes in oncogenes, tumor suppressor genes and reversible epigenetic changes. Different forms of epigenetic mechanisms have been shown to modify the expression of key genes during tumour progression. Promoter DNA hypermethylation of tumour suppressor genes or DNA repair genes, and covalent histone modifications appear in early stages of neoplasia. Methods to identify early markers in different types of cancer are being developed, although very few are specific and sensitive enough to be applied in the clinic. The aim of the present proposal is to develop sensitive and specific methodologies to identify early epigenetic markers for major types of cancer, like prostate and colorectal cancer. This project is based on recent findings that selected covalent histone modifications and their modifying enzymes can be early markers of tumourigenesis. For this purpose, the following will be applied. a) selected covalent histone modification like acetylation, methylation, phosphorylation, ubiquitination among others b) their modifying enzymes, like DNA (de)methylases and histone (de)acetylases, (de)methyltransferases c) appropriate diagnostic methods and tests for detection of selected markers in clinical samples. These markers are revealed from studies in cell and animal models as well from patient cohorts. Non-invasive diagnostic methods based on technologies developed in the participating organizations will be tested in clinical samples. Appropriately selected clinical samples will be utilized according to EU and national ethical procedures. The major task of this consortium will be the development of methods to be applied in the clinic for the immediate benefit of cancer patients.

Keywords: colorectal cancer,promoter gene methylation,histone modifying enzymes,prostate cancer,cancer epigenetic markers,diagnostic tests
Neutralizing antibodies against botulinum toxins A,B,E (ANTIBOTABE)

Framework: FP7 — Cooperation
Programme: Security
Destination: Restoring security and safety in case of crisis
Action type: Collaborative project
Countries involved: France,Germany,France,Finland,France,United Kingdom,United Kingdom
Call:  (FP7-SEC-2009-1, 2009)
Start date: 2010-09-01
End date: 2015-02-28
Duration (months): 54.0
Total project cost (EUR): 3896416.21
EU funding (EUR): 2966386.0
Participants: 10
Project status: CLOSED

Botulinum neurotoxins (BoNTs), the most toxic substances known, are susceptible for use as bioweapons (listed as class A agents by CDC). Currently licensed animal derived antibodies or F(ab’)2 preparations, are at a high risk of inducing adverse effects and their privately-owned stockpiles are limited. In this project, we will target the most lethal types of BoNTs: A (subtypes A1 and A2), B (B1 and B2) and E (E1). The antibodies will be directed against the C-terminus of the heavy chain and the light chain of each of these three BoNTs, as these domains contain neutralizing epitopes, according to the latest scientific data. The six corresponding immunogens will be produced in recombinant form, and utilized to immunize macaques (Macaca fascicularis), from which phage-displayed immune libraries will be built. Utilizing the phage technology, scFvs cross- reacting with A1 and A2, or B1 and B2subtypes will be panned. The best scFv from each library will be selected according to its high affinity and in vitro neutralization property. The six most neutralizing scFvs will then be super-humanized (“germline-humanized”) and expressed as IgGs, which will be tested in vivo, in a standardised model of protection and against toxins obtained from collections of clostridia strains. The project includes representatives of medical first-responders who will disseminate our results, and help create a market so that the necessary clinical studies could be performed in future. The project will offer an unequalled level of security against biothreats in Europe, based upon a family of well-tolerated and effective molecules.

Keywords: biodefense,recombinant antibodies,neutralization,toxin,clostridium botulinum,superhumanization
European NoVel Imaging Systems for ION therapy (ENVISION)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Switzerland,Germany,Austria,France,United Kingdom,Belgium,Italy,Germany,Germany,Netherlands,France,Spain,Belgium,Spain,Italy
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-02-01
End date: 2014-07-31
Duration (months): 54.0
Total project cost (EUR): 9305864.89
EU funding (EUR): 5996460.28
Participants: 16
Project status: CLOSED

Following the pioneering experiences which lasted several decades, particle therapy has become a recognized way of curing cancer. 2 new European dual-ion facilities (Heidelberg, Pavia) will soon become operational, followed by several others which are today at different stages of planning and construction. Hadron therapy faces the challenge of improving treatment outcomes with tools able to provide on-line a 4 dimensional feedback of the irradiation to enhance the dose conformation to the cancer volume and improve the treatment of moving organs. ENVISION is set up by 15 leading European research organisations, and 1 leading industrial partner IBA , to respond to these challenges. CERN is project coordinator and the majority of the key European experts in this field are involved, as well as the Hadron Research Facilities (Heidelberg, Pavia) who will immediately benefit from the developments foreseen in this project. A valorisation committee with members of the industrial partners has been established to maximally exploit the results. ENVISION tackles the problems of on-line Dose Monitoring and of performing accurate Quality Assurance tests by developing novel imaging modalities related to dose deposition and allow assessing the treated volume and deriving reliable indicators of the delivered dose. It concentrates on the detection of nuclear reaction products produced by the interaction of the beam with atomic nuclei of the tissue (positron emitting nuclides for ibPET, photons or light charged particles for ibSPAT). The methods are applicable to all therapy relevant ion species. The application of TOF techniques with superior time resolution to beam delivery integrated double head ibPET scanners has the potential for improving ibPET image quality. Furthermore, the real-time observation of the dose delivery process will become feasible for the 1st time, substantially reducing intervention times in case of treatment mistakes or incidents.

Keywords: tof (time of flight)-in beam-pet,single particle tomography,moving organs,in vivo dosimetry and monitoring,monte carlo,geant,phantom,ion therapy
Beta Cell Therapy in Diabetes (BETACELLTHERAPY)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Belgium,United Kingdom,United Kingdom,Netherlands,France,France,Israel,Switzerland,Belgium,Italy,Denmark,Norway,Belgium,United States
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2015-06-30
Duration (months): 66.0
Total project cost (EUR): 15919619.2
EU funding (EUR): 11700000.0
Participants: 18
Project status: CLOSED

Type 1 diabetes is a serious chronic disease with major health risks and heavy burden on patients and society. It is caused by massive immune-mediated loss of insulin-producing beta cells in the pancreas that can so far not be locally corrected. A cellular allotransplant in the liver can install a new beta cell mass but the size is insufficient and the procedure faces limitations of donor shortage, inaccessibility of the implants, risks of associated immunosuppression. Our consortium of research, clinical and bioindustry teams is focused on overcoming these obstacles and implementing a roadmap for translation to preclinical models and clinical trials. We will pursue three interacting tracks. First, our ability to induce beta cell progenitors and stimulate beta cell proliferation in vivo should lead us to cells and compounds that activate this process in a diabetic pancreas, thus activating endogenous beta cell regeneration. Second, we will produce human beta (progenitor) cells in vitro by derivation from stem cells as well as from reprogrammed autologous cells; their therapeutic potential will be compared to that of primary human beta cells following implantation in rodents using a site that is accessible to modulation and monitoring. Third, we will design an antibody-based therapy for inducing immune tolerance to regenerated beta cells and to a beta cell implant. Efficacy, safety and regulatory criteria will be determined for clinical implementation. Clinical protocols will be prepared by adjusting associated therapy and by adopting an accessible and controlled implant site. Clinical trials will benefit from state-of-the art biologic markers for comparative analysis of the developed forms of beta cell therapy. This program should provide proof of principle for strategies that make beta cell transplantation and beta cell regeneration realistic for large numbers of type 1 diabetic patients, and probably also for some categories of type 2 diabetes.

Keywords: diabetes,beta cells,cell transplantation,cell regeneration,cell therapy,stem cells,progenitor cells,transdifferentiation,immune reprogramming,clinical biologic markers
Cutaneous and Mucosal HIV Vaccination (CUT'HIVAC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,Germany,Spain,Finland,Germany,United Kingdom,United Kingdom,Mozambique,France,Peru
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2015-12-31
Duration (months): 72.0
Total project cost (EUR): 15439854.26
EU funding (EUR): 11929250.0
Participants: 18
Project status: CLOSED

Despite significant effort over the past decade to design and implement new vaccines strategies against HIV, no one has met its promise to prevent infection and/or to reduce viral load until reaching eradication of the HIV reservoir. To reach this goal, a translational research is critical to propose innovative approaches for an HIV vaccine enhancing broadly cross-reactive mucosal, humoral and cellular immune responses specific to HIV antigens. Composed by 13 partners from 5 European countries and 2 International Cooperation countries, the CUT’HIVAC consortium gathers knowledge’s and cutting-edge technologies in vaccinology and HIV diseases to raise the challenge of developing a new HIV strategy. The CUT’HIVAC approach is based on innovative transcutaneous and/or mucosal needle-free vaccination methods in a perspective that new vaccine candidates will redirect immune response toward cytotoxic CD8 and mucosal humoral responses. The trust of the project derives from the proof-of-concept that combination of routes of immunization and delivery systems will shape the immune responses towards its protective arms against HIV. Clinical trials will be implemented with last cutting-edge generation of HIV DNA-GTU® candidate applied by transcutaneous, intradermal routes and/or mucosal administration of HIV-envelop protein-based vaccine. Large efforts will be positioned on the new genetic design of HIV antigens and delivery systems for developed and developing countries. These new vaccines will be tested in innovative preclinical approaches with a special highlight on routes of vaccination that will be translated into 2nd round of clinical trials in a perspective that could help to prevent and eradicate HIV. Through its integrative and multidisciplinary approach, CUT’HIVAC will therefore provide the basis for a novel approach in vaccination with a view to wide its application to other infectious diseases such as malaria and tuberculosis.

Keywords: hiv vaccine,cutaneous vaccination,mucosal vaccination,vaccine strategy,aids,needle-free vaccination,clinical trial,transcutaneous route,hiv antigen,delivery system,infectious disease
CAMbrella – A pan-European research network for Complementary and Alternative Medicine (CAM) (CAMBRELLA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Coordination and support actions
Countries involved: Germany,Norway,Switzerland,United Kingdom,Germany,Sweden,France,Spain,Hungary,Romania,Denmark,Austria,Italy
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2012-12-31
Duration (months): 36.0
Total project cost (EUR): 1667439.8
EU funding (EUR): 1498597.0
Participants: 16
Project status: CLOSED

The goal of this collaboration is to develop a roadmap for future European research in CAM that is appropriate for the health care needs of EU citizens, and acceptable to the EU parliament as well as their national research funders and healthcare providers. We will enable meaningful reliable comparative research and communication within Europe and create a sustainable structure and policy. CAMbrella is focussed on academic research groups which do not advocate specific treatments. The Advisory Board represents the main CAM stakeholders including consumers, practitioners, clinical providers, and manufacturers of CAM medicinal products. The specific objectives are to develop an EU network involving centres of research excellence for collaborative research, to develop consensus-based terminology widely accepted in Europe to describe CAM interventions, to create a knowledge base that facilities our understanding of patient demand for CAM and its prevalence, to review the current legal status and policies governing CAM provision in the EU and, to explore the needs, beliefs and attitudes of the EU citizens with respect to CAM. Based on this information we will create a roadmap that will enable a sustainable and prioritised EU research roadmap for CAM. We will achieve this in 3 years by creating dialogue between researchers from 12 EU member and associated states. We will set up a mechanism that will allow fruitful and thoughtful discussion throughout the EU. To facilitate this coordinating action the project will be delivered in 9 independent but interrelated work packages whose members meet regularly. It will be coordinated by a Management Board and directed by a Scientific Steering Committee with support of an Advisory Board. The outcomes generated will be disseminated through our website, peer review publications and a final conference, with emphasis on current and future EU policies, addressing the different target audiences with an interest in CAM.

Keywords: complementary and alternative medicine,integrative medicine,terminology,legal status,prevalence of use,models of care,needs and attitudes,research roadmap
RAdiation-Shapes Thermal protection investigAtionS for high-SPeed EArth Re-entry (RASTAS SPEAR)

Framework: FP7 — Cooperation
Programme: Space
Destination: Strengthening the foundations of Space science and technology
Action type: Collaborative project
Countries involved: France,Italy,Switzerland,Greece,France,Poland,Czechia,Russian Federation,France,Belgium
Call:  (FP7-SPACE-2009-1, 2009)
Start date: 2010-09-01
End date: 2013-04-30
Duration (months): 32.0
Total project cost (EUR): 2404293.73
EU funding (EUR): 1607756.75
Participants: 10
Project status: CLOSED

In the frame of Activity 9.2.1 – Strengthening of Space foundations / Research to support space science and exploration - SPA.2009.2.1.01 Space Exploration, the actions proposed on RASTAS SPEAR project try to enlarge the basic capabilities on few known topics with low Technology Readiness Level and to strengthen European Industry and Research for coming or future Space Exploration missions with focus on Sample Return Missions like Marco Polo or Mars Sample return. The project does not analyse a specific mission but deals with crucial “bricks” to be well mastered for the design of a Capsule entering in the atmosphere with high speed (more than 10 km/s). These necessary bricks are: 1) To investigate on the available ground facilities and elaborate a proposal to improve these facilities in order to simulate in-flight conditions on ground. 2) to investigate and develop new and innovative methods, materials and systems for joining ablative blocks (tiles) together to produce a complete Thermal Protection System (TPS) for sample-return missions and validate them by tests with CIRA's Scirocco and DLR arcjet facility. 3) to identify and test damping, energy-absorbing systems to allow survival of the Capsule Payload (collected Samples from planets…) 4) to analyse the impact of ablation (and thus Capsule shape change) on the flight mechanics. 5) to investigate and test impact of surface roughness on the heat transfer between the flow field and the capsule heat shield. The return of invest for the European Community is a European capability to design carefully a Re-entry capsule with focus on mass and thus on mission cost.

Keywords: space exploration,high-speed re-entry,mars sample return,earth re-entry vehicle,thermal protection,radiation